Related Experiment Video
Updated: May 15, 2026

Mouse Models of Periventricular Leukomalacia
Published on: May 18, 2010
Surfactant protein D as a novel therapy for periventricular leukomalacia: is it the missing piece of the puzzle?
1Neonatology Department, Adnan Menderes University, Aydin, Turkey.
Abstract:
Activation of microglia with an inflammatory insult, which plays a central role in periventricular leukomalacia (PVL), results in premyelinating oligodendrocyte death via release of certain cytokines, reactive oxygen and nitrogen species. Toll-like receptor (TLR) 4 is necessary for lipopolysaccharide (LPS) induced oligodenrocyte injury in the CNS. Having an ability to bind TLR 2, 4, and LPS receptor CD14, surfactant protein D (spD) may be a promising agent to counteract the pathways associated with PVL. Supplementation of surfactant treatment with spD may be the key point in prevention of PVL by supression of inflammation and preventing damage to pre-OLs in a vulnerable premature brain operating through TLRs.
Insights
Surfactant protein D (spD) may prevent periventricular leukomalacia (PVL) by suppressing inflammation and protecting developing brain cells. This agent targets pathways involving Toll-like receptors (TLRs) and lipopolysaccharide (LPS).
Area of Science:
- Neuroscience
- Immunology
- Neonatal Research
Background:
- Periventricular leukomalacia (PVL) involves microglia activation and subsequent death of premyelinating oligodendrocytes.
- Toll-like receptor (TLR) 4 is implicated in lipopolysaccharide (LPS)-induced oligodendrocyte injury in the central nervous system (CNS).
Purpose of the Study:
- To investigate surfactant protein D (spD) as a potential therapeutic agent against PVL.
- To evaluate spD's ability to counteract inflammatory pathways in the premature brain.
Main Methods:
- The study focuses on the interaction of spD with TLR 2, TLR 4, and CD14.
- Investigating the role of TLRs in inflammatory insults leading to PVL.
Main Results:
- Surfactant protein D (spD) shows potential in binding to TLR 2, TLR 4, and CD14.
- spD may counteract inflammatory pathways implicated in PVL.
Conclusions:
- Supplementing surfactant treatment with spD could be crucial for preventing PVL.
- spD may protect vulnerable premature brains by suppressing inflammation and preventing pre-OL damage via TLRs.
